Merck announced the phase III KEYNOTE-181 trial investigating Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has met a primary endpoint of overall survival in patients whose tumors expressed PD-L1 (Combined Positive Score ≥10).
In this pivotal study, treatment with Keytruda resulted in a statistically significant improvement in OS compared to chemotherapy (paclitaxel, docetaxel, or irinotecan) in patients with CPS ≥10, regardless of histology.
The primary endpoint of OS was also evaluated in patients with squamous cell histology and in the entire intention-to-treat study population. While directionally favorable, statistical significance for OS was not met in these two patient groups.
Per the statistical analysis plan, the key secondary endpoints of progression-free survival and objective response rate were not formally tested, as OS was not reached in the full ITT study population.
The safety profile of Keytruda in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities worldwide.
KEYNOTE-181 is a randomized, open-label, phase III trial (ClinicalTrials.gov, NCT02564263) investigating Keytruda monotherapy compared to chemotherapy in patients with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, or Siewert type I adenocarcinoma of the esophagogastric junction that has progressed after first-line standard therapy.
The primary endpoint was OS (evaluated in all patients as well as in patients with PD-L1 CPS ≥10 and in patients with squamous cell carcinoma). Secondary endpoints were PFS, ORR and safety/tolerability.
The study enrolled more than 600 patients who were randomized 1:1 to receive either Keytruda (200 mg fixed dose every three weeks) or investigator’s choice of any of the following chemotherapy regimens, all given intravenously: docetaxel (75 mg/m^2 on Day 1 of each 21-day cycle), paclitaxel (80-100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle), or irinotecan (80 mg/m^2 on Day 1 of each 14-day cycle).
Keytruda significantly improved OS compared to chemotherapy in PD-L1 advanced esophageal or esophagogastric junction carcinoma
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.


Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality. It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...


A study led by researchers at the University of Pennsylvania has found that binary (yes/no) voting at the FDA Oncologic Drugs Advisory Committee can accurately capture the committee members’ perspectives in most cases.


Alan KormanAviv RegevJeffrey C. RathmellThe Cancer Research Institute announced the 2025 recipients of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology.

